News

CO2 EMISSION SAVINGS
At Moehs Group we are very committed to caring for our planet and our activity strictly complies with each and every one of our commitments.

2 GRANTS FROM CENTRO PARA EL DESARROLLO TECNOLÓGICO Y LA INNOVACIÓN
The Administration Board of the Centro para el Desarrollo Tecnológico y la Innovación, E.P.E (CDTI), has approved 2 important grants for Moehs Group: ABROCITINIB: development

VISIT TO EMIRATES FACILITIES
The traffic department of Moehs Group has had the opportunity to visit Emirates facilities at Barcelona Airport where they saw, first hand, how the air

Moehs Group member of CataloniaBio & HealthTech
From Moehs Group we would like to announce our incorporation as a member of the CataloniaBio & HealthTech platform. An entity that represents companies in

CARBON FOOTPRINT CERTIFICATE 2023
We are very proud to share the results obtained on the reduction of our carbon footprint! Once again, at Moehs Group, we continue striving and

INTERMON OXFAM TRAILWALKER SPONSORSHIP
On Sunday 7th April Oxfam Intermon organized the TRAILWALKER walk, the biggest sporting and solidarity challenge that consists of covering 100 km in 32 hours,

PARTICIPATION IN S3 INDUSTRY PROJECT
Moehs Group participates in the S3 Indústria project together with teachers from the Chemistry department of the Institutes Federica Montseny (Burjassot, Valencia) and Dr. Peset

PROJECT NITROSO-SITAGLIPTIN IMPURITY
We are proud to announce that the Moehs Research and Development project regarding nitroso-Sitagliptin impurity has been published by the scientific Journal of Separation Science

CPHI BARCELONA
Moehs Group participated in CPHI Barcelona, the great European event of the pharmaceutical sector. At our stand 6B40 in Hall 6, our team received hundreds

NEW JAPANESE PATENT FOR EDOXABAN
Moehs Group has just received Japanese patent JP7327736 for the API Edoxaban. This document is related to an improving method to produce EDOXABAN allowing us

NITROSAMINES PROJECT
We are proud to announce that Moehs has taken one step further on the nitrosamines project by publishing an article in the scientific Journal of

NEW MANAGEMENT TEAM
We announce the appointment of Mr. Javier del Rio as its new CEO replacing Mr. Francisco Escribano after a long career within Moehs. Mr. del

Publication in the scientific journal Biomedical Chromatography
We are pleased to share that a study developed by Moehs’ Research and Development team has been published in the scientific journal Biomedical Chromatography. This

Solar self-supply in 2024
During 2024, our photovoltaic plants generated a total of 1,628,153 kWh of energy, contributing significantly to the reduction of our carbon footprint: MOEHS CATALANA S.L.:

New Project Pharmaceuticals in the Environment
At Moehs Group, we continue to advance our commitment to sustainability as a member of the Pharmaceutical Supply Chain Initiative (PSCI). One of our priorities

XXII Conference on Good Manufacturing Practice for Medicines and Active Ingredients
Last 10th of December, our Site Manager, Josep Mª Casanovas, presented how we work at Moehs Group to continuously improve in the efficient use of

Moehs Group at the Pharmaceutical Manufacturing Catskills Training 2024
On 15th of November, Moehs Group team had the pleasure of collaborating in the Pharmaceutical Manufacturing Catskills 2024 training, organized at INS La Romànica, in

Moehs Group and EUROAPI sign an exclusive agreement for the production of Metamizole in Europe.
Moehs Group, a leading international group in the production of active pharmaceutical ingredients, has signed an exclusive agreement with EUROAPI to take over the production